Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.41 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16490970 | 0.84 | MGLL (0.33) | MGLLMEN1KMT2AALOX5ALKBH5 | |
| SCHEMBL3239509 | 0.81 | IDO1 (0.46) | MGLLALOX5ALDH1A1 | |
| SCHEMBL18849418 | 0.80 | CYP1A2 (0.32) | L3MBTL1 | |
| SCHEMBL17938253 | 0.80 | TSHR (0.44) | MEN1KMT2AALDH1A1 | |
| SCHEMBL16297129 | 0.80 | IDO1 (0.47) | MGLLMEN1KMT2AALOX5ALDH1A1 | |
| SCHEMBL5905967 | 0.80 | CYP1A2 (0.48) | MGLLALOX5ALDH1A1L3MBTL1NPBWR1 | |
| SCHEMBL18503917 | 0.80 | FAAH (0.46) | MGLL | |
| SCHEMBL18500802 | 0.80 | GRM1 (0.36) | ALDH1A1 | |
| SCHEMBL5906174 | 0.79 | NPC1 (0.42) | MGLLMEN1KMT2AALKBH5ALDH1A1 | |
| SCHEMBL4672478 | 0.78 | GAA (0.43) | ALDH1A1GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12110279-B2 | Triazolones, tetrazolones, and imidazolones, or their salts, and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2024-10-08 | — | — | US | disclosed |
| EP-4326715-A1 | TRIAZOLONES, TETRAZOLONES, AND IMIDAZOLONES, OR THEIR SALTS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Yuhan Corporation (KR) | 2024-02-28 | — | — | EP | disclosed |
| CN-117203205-A | Triazolone, tetrazolone and imidazolone or salts thereof, and pharmaceutical compositions containing the same | 柳韩洋行 | 2023-12-08 | — | — | CN | disclosed |
| US-20220380324-A1 | TRIAZOLONES, TETRAZOLONES, AND IMIDAZOLONES, OR THEIR SALTS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2022-12-01 | — | — | US | disclosed |
| WO-2022224195-A1 | TRIAZOLONES, TETRAZOLONES, AND IMIDAZOLONES, OR THEIR SALTS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2022-10-27 | — | — | WO | disclosed |
| EP-2841429-B1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | SUMITOMO CHEMICAL CO (JP) | 2020-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12110279-B2 | Triazolones, tetrazolones, and imidazolones, or their salts, and pharmaceutical compositions comprising the same | VAPB, VAPA, FABP1 | MGLL 1932/4885MEN1 3726/4885KMT2A 4667/4885 |
| US-20220380324-A1 | TRIAZOLONES, TETRAZOLONES, AND IMIDAZOLONES, OR THEIR SALTS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | VAPB, VAPA, FABP1 | MGLL 1932/4885MEN1 3726/4885KMT2A 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.